<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20802" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Functional Dyspepsia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Francis </surname>
            <given-names>Pilin</given-names>
          </name>
          <aff>Einstein Healthcare Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zavala</surname>
            <given-names>Stacey R.</given-names>
          </name>
          <aff>Einstein Healthcare Network</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pilin Francis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stacey Zavala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20802.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Functional dyspepsia is a common and benign gastrointestinal disorder that presents similarly to other conditions, making it difficult to diagnose. This condition is characterized by symptoms such as epigastric pain or burning, early satiety, and postprandial fullness, without any structural abnormalities detected via imaging or endoscopy. Functional dyspepsia affects over 20% of the population and is diagnosed based on symptom-based Rome IV Criteria.&#x000a0;Although the exact mechanism of functional dyspepsia is poorly understood, its pathophysiology is complex. Functional dyspepsia has 3 subtypes&#x02014;epigastric pain syndrome, postprandial distress syndrome, and a combination of the 2&#x02014;each thought to result from different mechanisms. Traditionally, functional dyspepsia has been attributed to disturbances in both macroscopic and microscopic gastric physiological factors. Initial management involves educating the patient about the diagnosis and discussing treatment expectations.&#x000a0;</p>
        <p>The primary treatment focuses on symptom management, as this disorder can be relapsing and remitting. Management primarily focuses on symptom relief, with treatment options including proton pump inhibitors, H2-receptor antagonists, prokinetic agents, and antidepressants. Patients should be tested and treated for <italic toggle="yes">Helicobacter pylori</italic> if applicable. Patients should be educated about their condition and treatment expectations. Endoscopic evaluation is necessary if alarming symptoms such as weight loss, dysphagia, or vomiting are present.&#x000a0;This activity reviews the evaluation and treatment of functional dyspepsia, emphasizing the vital role of the interprofessional healthcare team in effectively managing this condition and enhancing patient care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify symptoms of functional dyspepsia, including epigastric pain or burning, early satiety, and postprandial fullness, through comprehensive patient history and physical examination.</p></list-item><list-item><p>Implement evidence-based treatment strategies for functional dyspepsia, including lifestyle modifications, pharmacotherapy, and psychological interventions as indicated.</p></list-item><list-item><p>Apply guidelines for testing and treating <italic toggle="yes">Helicobacter pylori</italic> infection in patients with functional dyspepsia, considering age-specific risks and benefits.</p></list-item><list-item><p>Collaborate with the interprofessional healthcare team to coordinate comprehensive care plans for patients with functional dyspepsia by integrating patient education and lifestyle modifications into ongoing management strategies.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20802&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20802">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20802.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Functional dyspepsia is one of the most prevalent functional gastrointestinal disorders, affecting over 20% of the population. The condition has 3 subtypes&#x02014;epigastric pain syndrome, postprandial distress syndrome (PDS), and a combination of both&#x02014;each thought to result from different mechanisms. Diagnosis is based on the Rome IV criteria, which define functional dyspepsia as the presence of one or more symptoms, such as epigastric pain, burning, early satiety, and postprandial fullness, and in the absence of structural disease detectable by imaging or endoscopy. These symptoms may be severe enough to interfere with daily activities. While some patients may also experience nausea, vomiting, or heartburn, these symptoms are typically infrequent.<xref ref-type="bibr" rid="article-20802.r1">[1]</xref><xref ref-type="bibr" rid="article-20802.r2">[2]</xref><xref ref-type="bibr" rid="article-20802.r3">[3]</xref></p>
        <p>Patients should be tested and treated for <italic toggle="yes">Helicobacter pylori</italic> if applicable.<xref ref-type="bibr" rid="article-20802.r4">[4]</xref>&#x000a0;Further treatment involves symptom management with proton pump inhibitors (PPIs), H2-receptor antagonists (H2RAs), prokinetic agents, and antidepressants.<xref ref-type="bibr" rid="article-20802.r1">[1]</xref><xref ref-type="bibr" rid="article-20802.r4">[4]</xref> Alarming symptoms such as weight loss, dysphagia, or vomiting warrant an endoscopic evaluation.<xref ref-type="bibr" rid="article-20802.r5">[5]</xref></p>
      </sec>
      <sec id="article-20802.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Various&#x000a0;factors can cause symptoms of functional dyspepsia, including disturbed gastric motility, such as inadequate fundic accommodation or delayed gastric emptying, and disordered gastric sensation, such as hypersensitivity to gas and bloating. Additionally, gastric and duodenal inflammation can contribute to these symptoms. A genetic predisposition for functional dyspepsia is likely but less evident than in other functional gastrointestinal disorders such as irritable bowel syndrome (IBS). Psychiatric comorbidity and psychopathological states may also contribute to functional dyspepsia, although they are not specific to&#x000a0;the condition&#x000a0;and are less pronounced than in IBS.<xref ref-type="bibr" rid="article-20802.r1">[1]</xref></p>
      </sec>
      <sec id="article-20802.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Functional gastrointestinal disorders affect almost 40% of people worldwide.<xref ref-type="bibr" rid="article-20802.r6">[6]</xref>&#x000a0;The prevalence of functional dyspepsia&#x02014;a type of functional gastrointestinal disorder&#x02014;varies worldwide, with higher&#x000a0;rates of 10 to 40% in Western countries, including the United States. The global prevalence ranges from 5% to 11%.<xref ref-type="bibr" rid="article-20802.r7">[7]</xref><xref ref-type="bibr" rid="article-20802.r8">[8]</xref>&#x000a0;In Asian countries, the prevalence of&#x000a0;uninvestigated dyspepsia and&#x000a0;functional dyspepsia is 5% to 30%.<xref ref-type="bibr" rid="article-20802.r9">[9]</xref>&#x000a0;Functional dyspepsia is more common in women than in men.<xref ref-type="bibr" rid="article-20802.r10">[10]</xref> This difference is due to inherent sex-specific differences in gastrointestinal function. For example, sex-specific variation exists in hormone mechanisms, pain signaling, and healthcare maintenance.</p>
      </sec>
      <sec id="article-20802.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Although the exact mechanism is poorly understood, the pathophysiology of functional dyspepsia is complex, involving several different mechanisms thought to contribute to each subtype. Traditionally, disturbances in gastric physiologic factors, including both macroscopic and microscopic mechanisms, have been attributed to functional dyspepsia.</p>
        <p>Macroscopic physiological mechanisms include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gastroesophageal reflux disease (GERD).</p>
          </list-item>
          <list-item>
            <p>Delayed gastric emptying,&#x000a0;rapid gastric emptying, gastric dysrhythmias, and&#x000a0;antral hypomotility.<xref ref-type="bibr" rid="article-20802.r11">[11]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Visceral hypersensitivity alterations in the nervous system, including a lower threshold for pain in the presence of normal gastric compliance, abnormal&#x000a0;processing of afferent input in the spinal cord or brain, and dysfunction of&#x000a0;mechanoreceptors.<xref ref-type="bibr" rid="article-20802.r12">[12]</xref><xref ref-type="bibr" rid="article-20802.r13">[13]</xref></p>
          </list-item>
        </list>
        <p>Microscopic physiologic&#x000a0;mechanisms include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Impaired barrier function due to&#x000a0;altered sensitivity to duodenal acid or lipids that impair mucosal integrity.</p>
          </list-item>
          <list-item>
            <p>Gastroduodenal inflammation&#x000a0;characterized by&#x000a0;altered lymphocytes, including "gut-homing" lymphocytes, increased eosinophils, and mast cells.<xref ref-type="bibr" rid="article-20802.r14">[14]</xref><xref ref-type="bibr" rid="article-20802.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Altered gut microbiome and&#x000a0;<italic toggle="yes">H</italic><italic toggle="yes">&#x000a0;</italic><italic toggle="yes">pylori</italic>&#x000a0;infection&#x000a0;<xref ref-type="bibr" rid="article-20802.r16">[16]</xref><xref ref-type="bibr" rid="article-20802.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>Additional proof of the connection between intestinal inflammation and functional dyspepsia includes the discovery of increased small-bowel homing T lymphocytes in patients suffering from functional dyspepsia. These lymphocytes are positive for both &#x003b1;4&#x003b2;7-integrin and chemokine receptor 9. This finding is particularly significant because it has been strongly associated with cytokine release, including tumor necrosis factor-&#x003b1; (TNF-&#x003b1;).<xref ref-type="bibr" rid="article-20802.r18">[18]</xref><xref ref-type="bibr" rid="article-20802.r19">[19]</xref> Furthermore, it has been linked to an increase in the severity of symptoms and a delay in gastric emptying, thereby suggesting a crucial involvement of the duodenum in the development and progression of gastric disorders.<xref ref-type="bibr" rid="article-20802.r20">[20]</xref>&#x000a0;In addition, it can also result from&#x000a0;allergen exposure, which can lead to eosinophil recruitment in genetically predisposed patients.</p>
        <p>Psychological factors such as anxiety and depression can lead to increased activation of the amygdala and dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, indicating central processing of visceral stimuli from the gastrointestinal tract.&#x000a0;Stress activates the HPA axis, leading to the release of specific hormones from the hypothalamus and pituitary, culminating in the synthesis of cortisol. This process has been linked to increased cortisol levels and heightened HPA responses in patients with IBS.<xref ref-type="bibr" rid="article-20802.r21">[21]</xref>&#x000a0;Acute stress also increases salivary cortisol levels and intestinal permeability in healthy individuals.<xref ref-type="bibr" rid="article-20802.r22">[22]</xref>&#x000a0;Furthermore, a higher prevalence of functional gastrointestinal disorders is observed in patients with a history of childhood abuse.<xref ref-type="bibr" rid="article-20802.r23">[23]</xref><xref ref-type="bibr" rid="article-20802.r24">[24]</xref></p>
      </sec>
      <sec id="article-20802.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Typical symptoms of functional dyspepsia can be divided into 3 subtypes&#x02014;epigastric pain syndrome, PDS, and an overlap between the&#x000a0;2 syndromes. Symptoms can be acute or chronic. Patients should be asked about the severity and duration of symptoms. Symptom-based criteria are used to confirm the diagnosis. Any abnormal or progressive symptoms should be considered in the differential diagnoses.<xref ref-type="bibr" rid="article-20802.r25">[25]</xref></p>
        <p>
<bold>Rome IV Criteria for Functional Dyspepsia</bold>
</p>
        <p>In adults, functional dyspepsia with no evidence of structural disease is diagnosed with at least 1 of the&#x000a0;following symptoms present for&#x000a0;3 or more months, with&#x000a0;onset at least&#x000a0;6&#x000a0;months before diagnosis and affecting quality of life:</p>
        <list list-type="bullet">
          <list-item>
            <p>Postprandial fullness</p>
          </list-item>
          <list-item>
            <p>Epigastric pain</p>
          </list-item>
          <list-item>
            <p>Epigastric burning</p>
          </list-item>
          <list-item>
            <p>Early satiety</p>
          </list-item>
        </list>
        <p>
<bold>Subclassifications of Functional Dyspepsia</bold>
</p>
        <p>Functional dyspepsia is further classified into epigastric pain syndrome and PDS. Epigastric pain syndrome is characterized by epigastric pain or burning, while&#x000a0;PDS&#x000a0;is usually meal-induced and presents with postprandial fullness and early satiety.<xref ref-type="bibr" rid="article-20802.r26">[26]</xref></p>
        <p><bold>Epigastric pain syndrome: </bold>This condition, with no evidence of systemic, organic, or metabolic disease, is diagnosed when at least 1 of the following symptoms is present, severe enough to impact usual activities, occurring at least once per week for 3 or more months, with onset at least 6 months before diagnosis&#x02014;epigastric burning, epigastric pain, or both.</p>
        <p>Supportive criteria include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Postprandial epigastric bloating, nausea, and&#x000a0;belching</p>
          </list-item>
          <list-item>
            <p>Pain that does not meet biliary pain criteria</p>
          </list-item>
          <list-item>
            <p>Pain that may be provoked or relieved&#x000a0;by ingesting meals and can also occur while fasting</p>
          </list-item>
          <list-item>
            <p>Heartburn</p>
          </list-item>
        </list>
        <p><bold>Postprandial distress syndrome:&#x000a0;</bold>This condition, with no evidence of systemic, organic, or metabolic disease, is diagnosed when at least 1 of the following symptoms is present, severe enough to impact usual activities, occurring at least 3 days per week for 3 or more months, with onset at least 6 months before diagnosis&#x02014;postprandial fullness (that impacts the quality of life) or early satiety that prevents finishing a regular-size meal.</p>
        <p>Supportive symptoms include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Loss of appetite</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Retching</p>
          </list-item>
          <list-item>
            <p>Vomiting (persistent vomiting suggests&#x000a0;another condition)</p>
          </list-item>
          <list-item>
            <p>Postprandial epigastric pain or burning as with reflux</p>
          </list-item>
          <list-item>
            <p>Epigastric bloating</p>
          </list-item>
          <list-item>
            <p>Excessive belching</p>
          </list-item>
          <list-item>
            <p>Heartburn</p>
          </list-item>
          <list-item>
            <p>Symptoms of&#x000a0;IBS may also be present</p>
          </list-item>
        </list>
        <p>Notably,&#x000a0;symptoms relieved by flatus or defecation are typically not considered part of dyspepsia. Persistent vomiting could suggest a coexisting condition.</p>
      </sec>
      <sec id="article-20802.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluation begins with laboratory tests, including blood count, complete metabolic panel, thyroid function, celiac disease serology, and inflammatory markers. As&#x000a0;<italic toggle="yes">H pylori</italic>&#x000a0;infection is prevalent in at least 10% of the population, testing for this bacterium is recommended.<xref ref-type="bibr" rid="article-20802.r27">[27]</xref></p>
        <p>Instrumental examinations include esophagogastroduodenoscopy with biopsy and abdominal ultrasonography.&#x000a0;The American College of Gastroenterology (ACG) recommends routine use of upper endoscopy in patients aged 60 or older, irrespective of alarm symptoms, and for patients aged 60 or younger if alarm symptoms are present.</p>
        <p>Alarm symptoms include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Unintentional weight loss</p>
          </list-item>
          <list-item>
            <p>Difficulty swallowing (dysphagia)</p>
          </list-item>
          <list-item>
            <p>Painful swallowing (odynophagia)</p>
          </list-item>
          <list-item>
            <p>Unexplained iron deficiency anemia</p>
          </list-item>
          <list-item>
            <p>Persistent vomiting</p>
          </list-item>
          <list-item>
            <p>Detectable mass or lymphadenopathy</p>
          </list-item>
          <list-item>
            <p>Family history of upper gastrointestinal cancer&#x000a0;<xref ref-type="bibr" rid="article-20802.r28">[28]</xref></p>
          </list-item>
        </list>
        <p>If patients do not respond to treatment, pursuing more specialized testing specific to the symptoms is reasonable.<xref ref-type="bibr" rid="article-20802.r29">[29]</xref>&#x000a0;The diagnosis of functional dyspepsia is confirmed based on the patient&#x02019;s history and the exclusion of other diseases with similar presentations.</p>
      </sec>
      <sec id="article-20802.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treating functional dyspepsia can be challenging, with the primary goal being symptom control. Initial management involves educating the patient about the diagnosis and discussing treatment expectations.</p>
        <p>
<bold>Eradication of</bold>
<italic toggle="yes">
<bold> H pylori</bold>
</italic>
<bold> Infections</bold>
</p>
        <p>The global prevalence of <italic toggle="yes">H pylori</italic> infection exceeds 50% and&#x000a0;is recognized as a significant risk factor for conditions such as&#x000a0;chronic gastritis, peptic ulcers, gastric adenocarcinoma, GERD, and functional dyspepsia.<xref ref-type="bibr" rid="article-20802.r30">[30]</xref> Therefore, eradicating&#x000a0;<italic toggle="yes">H pylori</italic>&#x000a0;is recommended as the first-line treatment for all patients with functional dyspepsia.&#x000a0;Compared to no therapy, <italic toggle="yes">H pylori</italic> eradication therapy has a statistically significant, albeit small, benefit for relieving symptoms. This therapy&#x000a0;can also help reduce the development of peptic ulcer disease&#x000a0;and gastric cancer.<xref ref-type="bibr" rid="article-20802.r4">[4]</xref><xref ref-type="bibr" rid="article-20802.r31">[31]</xref>&#x000a0;Testing for the presence of&#x000a0;<italic toggle="yes">H pylori </italic>is usually performed during upper endoscopy to investigate dyspepsia. However,&#x000a0;if upper endoscopy is not indicated or the testing was not performed during the upper endoscopy,&#x000a0;the diagnosis of&#x000a0;<italic toggle="yes">H pylori</italic>&#x000a0;can be confirmed with a stool antigen assay or urea breath test.&#x000a0;To&#x000a0;ensure the accurate diagnosis of the patient with <italic toggle="yes">H pylori</italic>, they must refrain from&#x000a0;antibiotics for 4 weeks and PPIs for 1 to 2 weeks before the stool antigen test. Symptoms may be reduced when acid secretion changes or intestinal microbiota is modified.<xref ref-type="bibr" rid="article-20802.r30">[30]</xref><xref ref-type="bibr" rid="article-20802.r32">[32]</xref>&#x000a0;</p>
        <p>Various treatment regimes used for&#x000a0;<italic toggle="yes">H pylori</italic>&#x000a0;eradication include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bismuth quadruple therapy&#x000a0;includes the coadministration of bismuth subsalicylate, metronidazole, tetracycline, and a PPI such as omeprazole for 14 days. A combination capsule containing bismuth subcitrate, metronidazole, and tetracycline is approved by the United States Food and Drug Administration (FDA). North American trials reported a mean eradication rate of 91% with 10-day bismuth quadruple therapy.<xref ref-type="bibr" rid="article-20802.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clarithromycin-based therapy&#x000a0;includes triple, concurrent, and sequential therapies.<xref ref-type="bibr" rid="article-20802.r34">[34]</xref>&#x000a0;Triple therapy involves administering clarithromycin, amoxicillin, and a PPI twice daily for 14 days. With this regimen, eradication rates in the United States are typically below 80%. Concomitant&#x000a0;therapy combines clarithromycin, amoxicillin, metronidazole, and a PPI for 10 to 14 days. Sequential therapy consists of a 10-day regimen with clarithromycin, where patients take amoxicillin and a PPI for 5 days initially, followed by clarithromycin, metronidazole, and a PPI for the remaining 5 days.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hybrid therapy consists of 7 days of amoxicillin and a PPI, followed by another 7 days of amoxicillin, clarithromycin, metronidazole, and a PPI. Despite its complexity, this regimen has been suggested as an alternative to clarithromycin triple therapy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Levofloxacin-based therapy is only recommended for <italic toggle="yes">H pylori infection</italic> when sensitivity is confirmed or resistance rates are below 15%. This therapy can be part of triple, quadruple, or sequential therapy.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Vonoprazan-based regimens have high eradication rates in triple therapy with amoxicillin and clarithromycin or as dual therapy with high-dose amoxicillin. However, their effectiveness is dependent on clarithromycin resistance.<xref ref-type="bibr" rid="article-20802.r35">[35]</xref></p>
          </list-item>
        </list>
        <p>In case of treatment failure, some salvage therapies may also be used.&#x000a0;A study found rifabutin triple therapy similar to bismuth quadruple therapy for eradicating <italic toggle="yes">H pylori.</italic><xref ref-type="bibr" rid="article-20802.r36">[36]</xref> However, patients on rifabutin had better compliance and fewer adverse effects. This supports using rifabutin triple therapy as a salvage treatment for <italic toggle="yes">H pylori</italic>.</p>
        <p>After the successful eradication of <italic toggle="yes">H pylori</italic>, treatment is a 2-step process.&#x000a0;The first-line treatment involves a PPI or H2RA for at least&#x000a0;4 weeks. Then, if symptoms persist, subsequent treatment with tricyclic antidepressants (TCAs) or prokinetic agents such as metoclopramide and acotiamide (not available in the United States) is pursued.<xref ref-type="bibr" rid="article-20802.r37">[37]</xref><xref ref-type="bibr" rid="article-20802.r38">[38]</xref><xref ref-type="bibr" rid="article-20802.r39">[39]</xref><xref ref-type="bibr" rid="article-20802.r40">[40]</xref></p>
        <p>
<bold>Proton Pump Inhibitors</bold>
</p>
        <p>PPIs are recommended for 4 to 8 weeks for patients&#x000a0;who initially test negative for&#x000a0;<italic toggle="yes">H pylori</italic>&#x000a0;and those with persistent symptoms&#x000a0;4 weeks after the eradication of&#x000a0;<italic toggle="yes">H pylori</italic>&#x000a0;confirmed by&#x000a0;stool antigen testing,&#x000a0;urea breath test, or upper endoscopy-based testing. PPIs are believed to reduce mast cells, duodenal eosinophils, and mucosal permeability.<xref ref-type="bibr" rid="article-20802.r41">[41]</xref>&#x000a0;In patients showing improvement with PPIs, therapy should be discontinued every 6 to 12 months to mitigate long-term risks.</p>
        <p>The standard dosages of orally administered PPIs are&#x000a0;mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Lansoprazole: 30 mg daily</p>
          </list-item>
          <list-item>
            <p>Omeprazole: 20 mg daily</p>
          </list-item>
          <list-item>
            <p>Pantoprazole: 40 mg daily</p>
          </list-item>
          <list-item>
            <p>Rabeprazole: 20 mg daily</p>
          </list-item>
          <list-item>
            <p>Esomeprazole: 20 mg daily</p>
          </list-item>
        </list>
        <p>
<bold>H2-Receptor Antagonists</bold>
</p>
        <p>Further studies are required to validate the efficacy of H2RA treatment compared to PPI therapy. Several studies have demonstrated their effectiveness over placebo, showing a 23% reduction in symptoms.<xref ref-type="bibr" rid="article-20802.r42">[42]</xref></p>
        <p>
<bold>Antidepressants</bold>
</p>
        <p>Patients whose symptoms remain refractory after the initial 8 weeks of PPI therapy should discontinue PPIs, with consideration for initiating a TCA.<xref ref-type="bibr" rid="article-20802.r43">[43]</xref> For those who respond partially to PPIs, TCAs may be administered in combination with PPI therapy. The&#x000a0;recommended approaches are mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>The treatment can be initiated with either of the following low-dose TCAs at night:
<list list-type="bullet"><list-item><p>Amitriptyline: 10 mg&#x000a0;<xref ref-type="bibr" rid="article-20802.r44">[44]</xref></p></list-item><list-item><p>Nortriptyline: 10 mg</p></list-item><list-item><p>Desipramine: 25 mg</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>TCA doses may be cautiously titrated based on symptom responses;&#x000a0;higher doses may induce sedation without enhancing efficacy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>TCAs are initially administered for 8 to 12 weeks and then continued for&#x000a0;6 months&#x000a0;if the patient responds appropriately.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Doses must be gradually tapered to discontinue TCA use.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>TCAs may be resumed if symptoms recur.</p>
          </list-item>
        </list>
        <p>Mirtazapine has shown effectiveness in improving early satiation, nutrient tolerance, and gastrointestinal-specific anxiety, and in addressing unintentional weight loss.<xref ref-type="bibr" rid="article-20802.r45">[45]</xref><xref ref-type="bibr" rid="article-20802.r46">[46]</xref><xref ref-type="bibr" rid="article-20802.r45">[45]</xref>&#x000a0;Initial therapy typically begins with 7.5 mg, administered 1 hour before bedtime. Similar to other TCAs, starting with a low dose initially is advisable, which can be gradually increased up to 45 mg daily.</p>
        <p>
<bold>Prokinetic Agents</bold>
</p>
        <p>A 4- to 8-week course of a prokinetic agent is recommended when the aforementioned therapies fail or when symptoms recur. However, in some patients, adverse effects may lead to discontinuation of therapy. Therefore, treatment with minimal doses is advised (eg, domperidone 10 mg 3 times daily and metoclopramide use for less than 12 weeks).&#x000a0;Domperidone is linked to a slight increase in the risk of serious ventricular arrhythmias or sudden cardiac death, particularly in patients aged 60 or older, those taking daily doses over 30 mg, or those with factors predisposing them to QT prolongation.&#x000a0;Notably, it is contraindicated in patients with cardiac conduction prolongation, significant electrolyte disturbances, heart disease, moderate or severe liver impairment, and those taking QT-prolonging drugs and potent CYP3A4 inhibitors.<xref ref-type="bibr" rid="article-20802.r5">[5]</xref>&#x000a0;</p>
        <p>Metoclopramide 5 to 10 mg is usually administered 30 minutes before meals and at night.&#x000a0;Metoclopramide can cause tardive dyskinesia, a severe, often irreversible movement disorder. The risk increases with treatment duration and total dose; it should be discontinued if adverse effects develop. Some patients may see a reduction or resolution of the adverse effects after stopping metoclopramide. Metoclopramide can also increase the risk of psychosis and death in patients with dementia.<xref ref-type="bibr" rid="article-20802.r45">[45]</xref></p>
        <p>
<bold>Optional Therapies</bold>
</p>
        <p>Some patients may find the therapies below effective, although insufficient data exist to support their validation.</p>
        <list list-type="bullet">
          <list-item>
            <p>Psychotherapy: Although insufficient data on its efficacy exist, it is usually reserved for patients with associated stressors and those who fail to respond to medical therapy.<xref ref-type="bibr" rid="article-20802.r46">[46]</xref></p>
          </list-item>
          <list-item>
            <p>Buspirone: This drug may relax the gastric fundus when used 10 mg,&#x000a0;3 times daily for&#x000a0;4 weeks.&#x000a0;Patients treated with buspirone have shown improvement with early satiation.<xref ref-type="bibr" rid="article-20802.r47">[47]</xref></p>
          </list-item>
          <list-item>
            <p>Dietary modification.<xref ref-type="bibr" rid="article-20802.r48">[48]</xref></p>
          </list-item>
          <list-item>
            <p>Lifestyle modification.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20802.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The conditions below should be considered in the differential diagnosis.</p>
        <list list-type="bullet">
          <list-item>
            <p>GERD</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">H pylori</italic> infection&#x000a0;<xref ref-type="bibr" rid="article-20802.r49">[49]</xref></p>
          </list-item>
          <list-item>
            <p>Gastritis</p>
          </list-item>
          <list-item>
            <p>Peptic ulcer disease</p>
          </list-item>
          <list-item>
            <p>Celiac disease</p>
          </list-item>
          <list-item>
            <p>IBS&#x000a0;<xref ref-type="bibr" rid="article-20802.r50">[50]</xref></p>
          </list-item>
          <list-item>
            <p>Small intestinal bacterial overgrowth</p>
          </list-item>
          <list-item>
            <p>Chronic pancreatitis</p>
          </list-item>
          <list-item>
            <p>Gastroparesis&#x000a0;<xref ref-type="bibr" rid="article-20802.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Acute cholecystitis</p>
          </list-item>
          <list-item>
            <p>Gastric carcinoma</p>
          </list-item>
          <list-item>
            <p>Chronic abdominal pain</p>
          </list-item>
          <list-item>
            <p>Biliary pain</p>
          </list-item>
          <list-item>
            <p>Hepatocellular carcinoma&#x000a0;<xref ref-type="bibr" rid="article-20802.r51">[51]</xref></p>
          </list-item>
          <list-item>
            <p>Mesenteric ischemia</p>
          </list-item>
          <list-item>
            <p>Giardiasis</p>
          </list-item>
          <list-item>
            <p>Strongyloidiasis</p>
          </list-item>
          <list-item>
            <p>Sarcoidosis&#x000a0;<xref ref-type="bibr" rid="article-20802.r52">[52]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20802.s10" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <table-wrap id="article-20802.table0" position="float" orientation="portrait">
          <caption>
            <title>Table.&#x000a0;First-Line Therapies for&#x000a0;H pylori&#x000a0;Infection</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr style="height: 13px;">
                <td style="width: 130px; height: 13px; text-align: left; vertical-align: top;" rowspan="1" colspan="1">
<bold>Regimens</bold>
</td>
                <td style="width: 130.5px; height: 13px;" rowspan="1" colspan="1">
<bold>Drugs and Dosages</bold>
</td>
                <td style="width: 129.5px; height: 13px;" rowspan="1" colspan="1">
<bold>Dosing duration</bold>
</td>
              </tr>
              <tr style="height: 66px;">
                <td style="height: 66px; text-align: left; vertical-align: middle;" rowspan="1" colspan="1">Clarithromycin triple&#x000a0;<xref ref-type="bibr" rid="article-20802.r53">[53]</xref></td>
                <td style="text-align: left; vertical-align: top; height: 66px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>PPI regular dose twice a day</p></list-item><list-item><p>Clarithromycin 500 mg twice a day</p></list-item><list-item><p>Amoxicillin 1 g twice a day or metronidazole 500 mg thrice a day</p></list-item></list>
</td>
                <td style="width: 129.5px; height: 66px; text-align: left; vertical-align: middle;" rowspan="1" colspan="1">14 days&#x000a0;</td>
              </tr>
              <tr style="height: 93px;">
                <td style="width: 130px; height: 93px;" rowspan="1" colspan="1">Bismuth quadruple&#x000a0;<xref ref-type="bibr" rid="article-20802.r54">[54]</xref></td>
                <td style="text-align: left; vertical-align: top; height: 93px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>PPI regular dose twice a day</p></list-item><list-item><p>Bismuth subcitrate 120-300 mg or 420 mg&#x000a0;4 times a day</p></list-item><list-item><p>Tetracycline 500 mg&#x000a0;4 times a day</p></list-item><list-item><p>Metronidazole 250 mg (4 times a day) or 500 mg (3-4 times a day)</p></list-item></list>
</td>
                <td style="width: 129.5px; height: 93px;" rowspan="1" colspan="1">&#x000a0;10 to 14 days</td>
              </tr>
              <tr style="height: 1.22583px;">
                <td style="width: 130px; height: 1.22583px;" rowspan="1" colspan="1">Clarithromycin-based concomitant&#x000a0;<xref ref-type="bibr" rid="article-20802.r55">[55]</xref></td>
                <td style="width: 130.5px; height: 1.22583px;" rowspan="1" colspan="1">&#x000a0;
<list list-type="bullet"><list-item><p>PPI regular dose twice a day</p></list-item><list-item><p>Clarithromycin 500 mg twice a day</p></list-item><list-item><p>Amoxicillin 1 g twice a day</p></list-item><list-item><p>Metronidazole or tinidazole 500 mg twice a day</p></list-item></list>
</td>
                <td style="width: 129.5px; height: 1.22583px;" rowspan="1" colspan="1">&#x000a0;10 to 14 days</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 130px; height: 13px;" rowspan="1" colspan="1">Clarithromycin-based hybrid&#x000a0;<xref ref-type="bibr" rid="article-20802.r56">[56]</xref></td>
                <td style="width: 130.5px; height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>PPI standard dose</p></list-item><list-item><p>Amoxicillin 1 g twice a day for&#x000a0;7 days followed by PPI, amoxicillin, clarithromycin 500 mg, plus either&#x000a0;tinidazole 500 mg or metronidazole for an additional&#x000a0;7 days</p></list-item></list>
</td>
                <td style="width: 129.5px; height: 13px;" rowspan="1" colspan="1">&#x000a0;Total 14 days</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 130px; height: 13px;" rowspan="1" colspan="1">Clarithromycin-based sequential&#x000a0;<xref ref-type="bibr" rid="article-20802.r57">[57]</xref></td>
                <td style="width: 130.5px; height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>PPI standard dose</p></list-item><list-item><p>Amoxicillin 1 g twice a day for&#x000a0;5 days followed by PPI, clarithromycin 500 mg plus either&#x000a0;tinidazole 500 mg or metronidazole for an additional&#x000a0;5 days</p></list-item></list>
</td>
                <td style="width: 129.5px; height: 13px;" rowspan="1" colspan="1">Total 10 days</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-20802.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Functional dyspepsia is characterized by a relapsing and remitting course, with periods of symptom relief interspersed with flare-ups. While lifestyle changes, medications, and sometimes psychotherapy can provide significant relief for some patients, others may experience persistent symptoms over an extended period. Studies indicate that approximately half of individuals diagnosed with functional dyspepsia continue to experience symptoms up to a year after diagnosis.</p>
        <p>A&#x000a0;study found that patients with functional dyspepsia had a similar quality of life compared to those with peptic ulcer disease, and their quality of life was significantly worse than healthy individuals.<xref ref-type="bibr" rid="article-20802.r58">[58]</xref></p>
      </sec>
      <sec id="article-20802.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Although functional dyspepsia is not associated with increased mortality, it does cause significant physical and mental distress, impacting the patient&#x02019;s quality of life. Patients with functional dyspepsia often score higher on psychometric tests for symptoms of anxiety, depression, and somatization. Approximately 10% to 25% of patients report that the social impact of their symptoms is significant enough to seek medical attention, resulting in increased healthcare visits, significant health impairment, and a decline in overall quality of life.</p>
      </sec>
      <sec id="article-20802.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Patients usually present to family practitioners, internists, or nurse practitioners for their initial symptoms. Based on the severity and nature of the symptoms, a consultation with a gastroenterologist may be necessary&#x000a0;for an endoscopy. Depending on the patient's symptoms, a consultation with a dietitian could be beneficial to address dietary concerns. Additionally, a mental health professional may be involved if stress or mental health issues are contributing to the condition.</p>
      </sec>
      <sec id="article-20802.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Educating patients on the benign course of this disorder and establishing long-term care and expectations for treatment is essential.<xref ref-type="bibr" rid="article-20802.r3">[3]</xref>&#x000a0;Patients should be informed to promptly report red flag signs such as unintentional weight loss, persistent vomiting, or dysphagia and understand that further evaluation may be necessary.</p>
      </sec>
      <sec id="article-20802.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Functional dyspepsia is a relatively common condition that prompts patients to seek medical attention.&#x000a0;Patients have symptoms that may mimic other conditions. More invasive testing is also essential to rule out any potential organic causes of the symptoms, especially if red flag signs are present.&#x000a0;Diagnosis can be challenging, relying on clinical assessment aligned with patient history and symptoms meeting the Rome IV criteria.</p>
        <p>Treatment can be equally challenging because symptoms are frequently refractory to first-line therapies. An interprofessional healthcare team of primary care physicians, advanced practice clinicians, gastroenterologists, nurses, psychiatrists, and pharmacists is critical in recognizing and effectively managing this condition for patients.</p>
      </sec>
      <sec id="article-20802.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20802&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20802">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/functional-dyspepsia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20802">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20802/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20802">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20802.s17">
        <title>References</title>
        <ref id="article-20802.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Enck</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Azpiroz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Boeckxstaens</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Elsenbruch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feinle-Bisset</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Holtmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lackner</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ronkainen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schemann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stengel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tack</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zipfel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Talley</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Functional dyspepsia.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2017</year>
            <month>Nov</month>
            <day>03</day>
            <volume>3</volume>
            <fpage>17081</fpage>
            <pub-id pub-id-type="pmid">29099093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>KD</given-names>
              </name>
              <collab>Korean Society of Neurogastroenterology and Motility</collab>
            </person-group>
            <article-title>[Current issues in functional dyspepsia].</article-title>
            <source>Korean J Gastroenterol</source>
            <year>2014</year>
            <month>Sep</month>
            <day>25</day>
            <volume>64</volume>
            <issue>3</issue>
            <fpage>133</fpage>
            <page-range>133-41</page-range>
            <pub-id pub-id-type="pmid">25252861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madisch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andresen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Enck</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Labenz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frieling</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schemann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The Diagnosis and Treatment of Functional Dyspepsia.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2018</year>
            <month>Mar</month>
            <day>30</day>
            <volume>115</volume>
            <issue>13</issue>
            <fpage>222</fpage>
            <page-range>222-232</page-range>
            <pub-id pub-id-type="pmid">29669681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oshima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miwa</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>New Approaches to Diagnosis and Treatment of Functional Dyspepsia.</article-title>
            <source>Curr Gastroenterol Rep</source>
            <year>2018</year>
            <month>Oct</month>
            <day>18</day>
            <volume>20</volume>
            <issue>12</issue>
            <fpage>55</fpage>
            <pub-id pub-id-type="pmid">30338390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moayyedi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lacy</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Enns</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Howden</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Vakil</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>ACG and CAG Clinical Guideline: Management of Dyspepsia.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>112</volume>
            <issue>7</issue>
            <fpage>988</fpage>
            <page-range>988-1013</page-range>
            <pub-id pub-id-type="pmid">28631728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sperber</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Bangdiwala</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Drossman</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Ghoshal</surname>
                <given-names>UC</given-names>
              </name>
              <name>
                <surname>Simren</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tack</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Whitehead</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Dumitrascu</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Fukudo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kellow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Okeke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Quigley</surname>
                <given-names>EMM</given-names>
              </name>
              <name>
                <surname>Schmulson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Whorwell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Archampong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Adibi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Andresen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Benninga</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bonaz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Corazziari</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Francisconi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lazebnik</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Mulak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Setshedi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Syam</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Vanner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Lopez-Colombo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dickman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kanazawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Keshteli</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Khatun</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maleki</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Poitras</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pratap</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stefanyuk</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Thomson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zeevenhooven</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Palsson</surname>
                <given-names>OS</given-names>
              </name>
            </person-group>
            <article-title>Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study.</article-title>
            <source>Gastroenterology</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>160</volume>
            <issue>1</issue>
            <fpage>99</fpage>
            <page-range>99-114.e3</page-range>
            <pub-id pub-id-type="pmid">32294476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ford</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Marwaha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moayyedi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis.</article-title>
            <source>Gut</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>64</volume>
            <issue>7</issue>
            <fpage>1049</fpage>
            <page-range>1049-57</page-range>
            <pub-id pub-id-type="pmid">25147201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aziz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Palsson</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Whitehead</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Sperber</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Simr&#x000e9;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>T&#x000f6;rnblom</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology, Clinical Characteristics, and Associations for Rome IV Functional Nausea and Vomiting Disorders in Adults.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>878</fpage>
            <page-range>878-886</page-range>
            <pub-id pub-id-type="pmid">29857155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghoshal</surname>
                <given-names>UC</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Kachintorn</surname>
                <given-names>U</given-names>
              </name>
              <collab>Functional Dyspepsia Consensus Team of the Asian Neurogastroenterology and Motility Association and the Asian Pacific Association of Gastroenterology</collab>
            </person-group>
            <article-title>Epidemiology of uninvestigated and functional dyspepsia in Asia: facts and fiction.</article-title>
            <source>J Neurogastroenterol Motil</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>235</fpage>
            <page-range>235-44</page-range>
            <pub-id pub-id-type="pmid">21860815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sud</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pebbili</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Bhagat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rathod</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mane</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kotak</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Dyspepsia - The Indian perspective: A cross sectional study on demographics and treatment patterns of Dyspepsia from across India (Power 1.0 study).</article-title>
            <source>J Assoc Physicians India</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>11</fpage>
            <page-range>11-12</page-range>
            <pub-id pub-id-type="pmid">37355791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Acosta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Camilleri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Harmsen</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Szarka</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Gastric Motor Dysfunction in Patients With Functional Gastroduodenal Symptoms.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>112</volume>
            <issue>11</issue>
            <fpage>1689</fpage>
            <page-range>1689-1699</page-range>
            <pub-id pub-id-type="pmid">28895582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Cocjin</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Schurman</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Friesen</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Visceral hypersensitivity and electromechanical dysfunction as therapeutic targets in pediatric functional dyspepsia.</article-title>
            <source>World J Gastrointest Pharmacol Ther</source>
            <year>2014</year>
            <month>Aug</month>
            <day>06</day>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>122</fpage>
            <page-range>122-38</page-range>
            <pub-id pub-id-type="pmid">25133041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farr&#x000e9;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vanheel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vanuytsel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Masaoka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>T&#x000f6;rnblom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Simr&#x000e9;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Oudenhove</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tack</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>In functional dyspepsia, hypersensitivity to postprandial distention correlates with meal-related symptom severity.</article-title>
            <source>Gastroenterology</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>145</volume>
            <issue>3</issue>
            <fpage>566</fpage>
            <page-range>566-73</page-range>
            <pub-id pub-id-type="pmid">23702005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ye</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>XR</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>GX</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>CZ</given-names>
              </name>
            </person-group>
            <article-title>Choosing an Animal Model for the Study of Functional Dyspepsia.</article-title>
            <source>Can J Gastroenterol Hepatol</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>1531958</fpage>
            <pub-id pub-id-type="pmid">29623262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Du</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Corrigendum: Increased Duodenal Eosinophil Degranulation in Patients with Functional Dyspepsia: A Prospective Study.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Apr</month>
            <day>07</day>
            <volume>7</volume>
            <fpage>46121</fpage>
            <pub-id pub-id-type="pmid">28387752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahman</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ghoshal</surname>
                <given-names>UC</given-names>
              </name>
              <name>
                <surname>Sultana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kibria</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Sultana</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sarker</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Gastrointestinal Consequences are Frequent Following Sporadic Acute Infectious Diarrhea in a Tropical Country: A Prospective Cohort Study.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>113</volume>
            <issue>9</issue>
            <fpage>1363</fpage>
            <page-range>1363-1375</page-range>
            <pub-id pub-id-type="pmid">30171215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iwata</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sugimoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morino</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Akimoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hamada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Niikura</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nagata</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Improvement of dyspeptic symptoms after <italic>Helicobacter pylori</italic> eradication therapy in Japanese patients.</article-title>
            <source>JGH Open</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>12</issue>
            <fpage>855</fpage>
            <page-range>855-862</page-range>
            <pub-id pub-id-type="pmid">38162864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liebregts</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bredack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gururatsakul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pilkington</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Brierley</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Blackshaw</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Gerken</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Talley</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Holtmann</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>106</volume>
            <issue>6</issue>
            <fpage>1089</fpage>
            <page-range>1089-98</page-range>
            <pub-id pub-id-type="pmid">21245834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burns</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Bruce</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Minahan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mathe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fairlie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Naudin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Potter</surname>
                <given-names>MDE</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Bollipo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koloski</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Horvat</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Veysey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Holtmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Talley</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Keely</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Type 2 and type 17 effector cells are increased in the duodenal mucosa but not peripheral blood of patients with functional dyspepsia.</article-title>
            <source>Front Immunol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>1051632</fpage>
            <pub-id pub-id-type="pmid">36685573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azpiroz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Feinle-Bisset</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grundy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tack</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Gastric sensitivity and reflexes: basic mechanisms underlying clinical problems.</article-title>
            <source>J Gastroenterol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>206</fpage>
            <page-range>206-18</page-range>
            <pub-id pub-id-type="pmid">24306100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Greenwood-Van Meerveld</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mawe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shea-Donohue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Verdu</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grundy</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Fundamentals of Neurogastroenterology: Basic Science.</article-title>
            <source>Gastroenterology</source>
            <year>2016</year>
            <month>Feb</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">27144618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanuytsel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Wanrooy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vanheel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vanormelingen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Verschueren</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Houben</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Salim Rasoel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>T&#x003cc;th</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holvoet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Farr&#x000e9;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Van Oudenhove</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boeckxstaens</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Verbeke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tack</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism.</article-title>
            <source>Gut</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>63</volume>
            <issue>8</issue>
            <fpage>1293</fpage>
            <page-range>1293-9</page-range>
            <pub-id pub-id-type="pmid">24153250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oshima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fukui</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Watari</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Miwa</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Childhood abuse history is associated with the development of dyspepsia: a population-based survey in Japan.</article-title>
            <source>J Gastroenterol</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>50</volume>
            <issue>7</issue>
            <fpage>744</fpage>
            <page-range>744-50</page-range>
            <pub-id pub-id-type="pmid">25416144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dibaise</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Islam</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Dueck</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Roarke</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Crowell</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Psychological distress in Rome III functional dyspepsia patients presenting for testing of gastric emptying.</article-title>
            <source>Neurogastroenterol Motil</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>196</fpage>
            <page-range>196-205</page-range>
            <pub-id pub-id-type="pmid">26511077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooke</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Gormley</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Gilliland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cupples</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Dyspepsia.</article-title>
            <source>BMJ</source>
            <year>2011</year>
            <month>Sep</month>
            <day>30</day>
            <volume>343</volume>
            <fpage>d6234</fpage>
            <pub-id pub-id-type="pmid">21964545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zagari</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Fuccio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cennamo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gilthorpe</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bazzoli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study.</article-title>
            <source>Gastroenterology</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>138</volume>
            <issue>4</issue>
            <fpage>1302</fpage>
            <page-range>1302-11</page-range>
            <pub-id pub-id-type="pmid">20074574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voirol-Perrin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stamm</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Salvador Nunes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schoepfer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Functional dyspepsia : update 2023].</article-title>
            <source>Rev Med Suisse</source>
            <year>2023</year>
            <month>Aug</month>
            <day>30</day>
            <volume>19</volume>
            <issue>839</issue>
            <fpage>1554</fpage>
            <page-range>1554-1557</page-range>
            <pub-id pub-id-type="pmid">37650593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Machhan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bodh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Dyspepsia with alarm symptoms in patients aged less than 60 years: Is upper gastrointestinal endoscopy justified in Indian scenario?</article-title>
            <source>Indian J Gastroenterol</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>430</fpage>
            <page-range>430-439</page-range>
            <pub-id pub-id-type="pmid">36308702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsu</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Azzopardi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Broad</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and disease burden of gastroparesis in Asia.</article-title>
            <source>J Gastroenterol Hepatol</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>649</fpage>
            <page-range>649-657</page-range>
            <pub-id pub-id-type="pmid">38224680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Relationship between <italic>Helicobacter pylori</italic> infection and gastrointestinal microecology.</article-title>
            <source>Front Cell Infect Microbiol</source>
            <year>2022</year>
            <volume>12</volume>
            <fpage>938608</fpage>
            <pub-id pub-id-type="pmid">36061875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Addula</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>VED</given-names>
              </name>
              <name>
                <surname>Reddymasu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Immunopathological and molecular basis of functional dyspepsia and current therapeutic approaches.</article-title>
            <source>Expert Rev Clin Immunol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>831</fpage>
            <page-range>831-840</page-range>
            <pub-id pub-id-type="pmid">30235962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazzoleni</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Francesconi</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Mazzoleni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Uchoa</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>De Bona</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Milbradt</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Von Reisswitz</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Berwanger</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bressel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Edelweiss</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Marini</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Folador</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lunkes</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Heck</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Birkhan</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Spindler</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>Bda S</given-names>
              </name>
              <name>
                <surname>Guerrieri</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Renck</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Grando</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hocevar de Moura</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dahmer</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Rauber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Prolla</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Helicobacter pylori eradication in functional dyspepsia: HEROES trial.</article-title>
            <source>Arch Intern Med</source>
            <year>2011</year>
            <month>Nov</month>
            <day>28</day>
            <volume>171</volume>
            <issue>21</issue>
            <fpage>1929</fpage>
            <page-range>1929-36</page-range>
            <pub-id pub-id-type="pmid">22123802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malfertheiner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bazzoli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Delchier</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Celi&#x000f1;ski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gigu&#x000e8;re</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rivi&#x000e8;re</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000e9;graud</surname>
                <given-names>F</given-names>
              </name>
              <collab>Pylera Study Group</collab>
            </person-group>
            <article-title>Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2011</year>
            <month>Mar</month>
            <day>12</day>
            <volume>377</volume>
            <issue>9769</issue>
            <fpage>905</fpage>
            <page-range>905-13</page-range>
            <pub-id pub-id-type="pmid">21345487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alfadhli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alboraie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Afifi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dangi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A Randomized Clinical Trial Comparing Triple Therapy versus Non-bismuth based Quadruple Therapy for the Eradication of <italic>Helicobacter Pylori</italic> in Kuwait.</article-title>
            <source>J Glob Infect Dis</source>
            <year>2022</year>
            <season>Jul-Sep</season>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>99</fpage>
            <page-range>99-105</page-range>
            <pub-id pub-id-type="pmid">36237565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>QZ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Mu</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Duan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>ZX</given-names>
              </name>
              <name>
                <surname>Zuo</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YQ</given-names>
              </name>
            </person-group>
            <article-title>Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.</article-title>
            <source>J Dig Dis</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-27</page-range>
            <pub-id pub-id-type="pmid">36960538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial.</article-title>
            <source>J Infect Dis</source>
            <year>2023</year>
            <month>Aug</month>
            <day>31</day>
            <volume>228</volume>
            <issue>5</issue>
            <fpage>511</fpage>
            <page-range>511-518</page-range>
            <pub-id pub-id-type="pmid">37079894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koduru</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quigley</surname>
                <given-names>EMM</given-names>
              </name>
            </person-group>
            <article-title>Definition, Pathogenesis, and Management of That&#x000a0;Cursed&#x000a0;Dyspepsia.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>467</fpage>
            <page-range>467-479</page-range>
            <pub-id pub-id-type="pmid">28899670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simr&#x000e9;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tack</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Functional dyspepsia: evaluation and treatment.</article-title>
            <source>Gastroenterol Clin North Am</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>577</fpage>
            <page-range>577-99</page-range>
            <pub-id pub-id-type="pmid">12858607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tack</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Masaoka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Functional dyspepsia.</article-title>
            <source>Curr Opin Gastroenterol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>549</fpage>
            <page-range>549-57</page-range>
            <pub-id pub-id-type="pmid">21934617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanheel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tack</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic options for functional dyspepsia.</article-title>
            <source>Dig Dis</source>
            <year>2014</year>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>230</fpage>
            <page-range>230-4</page-range>
            <pub-id pub-id-type="pmid">24732188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wauters</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ceulemans</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frings</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lambaerts</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Accarie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mols</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Augustijns</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>De Hertogh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Van Oudenhove</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tack</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vanuytsel</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Proton Pump Inhibitors Reduce Duodenal Eosinophilia, Mast Cells, and Permeability in Patients With Functional Dyspepsia.</article-title>
            <source>Gastroenterology</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>160</volume>
            <issue>5</issue>
            <fpage>1521</fpage>
            <page-range>1521-1531.e9</page-range>
            <pub-id pub-id-type="pmid">33346007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moayyedi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Soo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deeks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Innes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological interventions for non-ulcer dyspepsia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2006</year>
            <month>Oct</month>
            <day>18</day>
            <issue>4</issue>
            <fpage>CD001960</fpage>
            <pub-id pub-id-type="pmid">17054151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacy</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Camilleri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bouras</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>DiBaise</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Herrick</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Szarka</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Tilkes</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zinsmeister</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Talley</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of Antidepressants on Gastric Function in Patients with Functional Dyspepsia.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>113</volume>
            <issue>2</issue>
            <fpage>216</fpage>
            <page-range>216-224</page-range>
            <pub-id pub-id-type="pmid">29257140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Talley</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Locke</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Almazar</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Bouras</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Howden</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Lacy</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>DiBaise</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Prather</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>El-Serag</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Moayyedi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Herrick</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Szarka</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Camilleri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Schleck</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Tilkes</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Zinsmeister</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study.</article-title>
            <source>Gastroenterology</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>149</volume>
            <issue>2</issue>
            <fpage>340</fpage>
            <page-range>340-9.e2</page-range>
            <pub-id pub-id-type="pmid">25921377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jenkins</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Review of Dopamine Antagonists for Nausea and Vomiting in Palliative Care Patients.</article-title>
            <source>J Pain Palliat Care Pharmacother</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-44</page-range>
            <pub-id pub-id-type="pmid">37843383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moayyedi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Deeks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Psychological interventions for non-ulcer dyspepsia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2005</year>
            <month>Apr</month>
            <day>18</day>
            <issue>2</issue>
            <fpage>CD002301</fpage>
            <pub-id pub-id-type="pmid">15846636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caviglia</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Sguazzini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cisar&#x000f2;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ribaldone</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Rosso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fagoonee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smedile</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saracco</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Astegiano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pellicano</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic Acid Breath Test.</article-title>
            <source>Minerva Med</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>489</fpage>
            <page-range>489-495</page-range>
            <pub-id pub-id-type="pmid">28707862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duncanson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pryor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keely</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Talley</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Food-Induced Symptom Induction and Dietary Management in Functional Dyspepsia.</article-title>
            <source>Nutrients</source>
            <year>2021</year>
            <month>Mar</month>
            <day>28</day>
            <volume>13</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">33800668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Adhikari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Katila</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bajracharya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bohara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pathak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Poudel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sapkota</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Helicobacter pylori Infection among Patients Undergoing Upper Gastrointestinal Endoscopy in a Tertiary Care Center.</article-title>
            <source>JNMA J Nepal Med Assoc</source>
            <year>2024</year>
            <month>Jan</month>
            <day>02</day>
            <volume>62</volume>
            <issue>269</issue>
            <fpage>5</fpage>
            <page-range>5-8</page-range>
            <pub-id pub-id-type="pmid">38410016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000e1;rdos</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Irritable bowel syndrome (IBS): could we decide what is behind?</article-title>
            <source>Biol Futur</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-71</page-range>
            <pub-id pub-id-type="pmid">38386191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Georgescu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lighezan</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Rosca</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Nistor</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ancusa</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Suceava</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Iancu</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kundnani</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>NASH/NAFLD-Related Hepatocellular Carcinoma: An Added Burden.</article-title>
            <source>Life (Basel)</source>
            <year>2023</year>
            <month>Dec</month>
            <day>23</day>
            <volume>14</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">38255641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gala</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Luckett</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Gastric Sarcoidosis Presenting As Dyspepsia.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Feb</month>
            <day>29</day>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>e7139</fpage>
            <pub-id pub-id-type="pmid">32257684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fallone</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Chiba</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>van Zanten</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Fischbach</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gisbert</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Render</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leontiadis</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Moayyedi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.</article-title>
            <source>Gastroenterology</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>151</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-69.e14</page-range>
            <pub-id pub-id-type="pmid">27102658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McColl</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice. Helicobacter pylori infection.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Apr</month>
            <day>29</day>
            <volume>362</volume>
            <issue>17</issue>
            <fpage>1597</fpage>
            <page-range>1597-604</page-range>
            <pub-id pub-id-type="pmid">20427808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gisbert</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Calvet</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.</article-title>
            <source>Clin Exp Gastroenterol</source>
            <year>2012</year>
            <volume>5</volume>
            <fpage>23</fpage>
            <page-range>23-34</page-range>
            <pub-id pub-id-type="pmid">22457599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yeo</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Shiu</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Liou</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CY</given-names>
              </name>
              <collab>Taiwan Gastrointestinal Disease and Helicobacter Consortium</collab>
            </person-group>
            <article-title>First-line <italic>Helicobacter pylori</italic> eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis.</article-title>
            <source>Gut</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-27</page-range>
            <pub-id pub-id-type="pmid">27670375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moayyedi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Malfertheiner</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn?</article-title>
            <source>Am J Gastroenterol</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>104</volume>
            <issue>12</issue>
            <fpage>3081</fpage>
            <page-range>3081-3</page-range>
            <pub-id pub-id-type="pmid">19956122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20802.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Serag</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Talley</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Health-related quality of life in functional dyspepsia.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2003</year>
            <month>Aug</month>
            <day>15</day>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>387</fpage>
            <page-range>387-93</page-range>
            <pub-id pub-id-type="pmid">12940923</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
